Review article: The assessment and management of chronic severe gastrointestinal dysmotility in adults

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 10, 2013, Pages 1209-1229

  Paine, P ^a,b   McLaughlin, J ^a   Lal, S ^a  

^a SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; ANTIBIOTIC AGENT; AZATHIOPRINE; BACLOFEN; BUSERELIN; CISAPRIDE; CLONIDINE; CYCLOPHOSPHAMIDE; DOMPERIDONE; FLUDARABINE; METHADONE; METOCLOPRAMIDE; NALOXONE; PHENYTOIN; PYRIDOSTIGMINE; RITUXIMAB; STEROID; TRAMADOL; VERAPAMIL;

AMYLOIDOSIS; AUTOIMMUNE DISEASE; AUTONOMIC NEUROPATHY; BONE DENSITY; BOTULISM; CAPSULE ENDOSCOPY; CELIAC DISEASE; CHAGAS DISEASE; CLINICAL ASSESSMENT; COLON RESECTION; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENTERIC FEEDING; ENTERITIS; GASTROINTESTINAL MOTILITY DISORDER; GASTROINTESTINAL NEUROMUSCULAR DISEASES; GLUTEN FREE DIET; HERPES VIRUS; HUMAN; HYDROGEN BREATH TEST; HYPERBARIC OXYGEN; ILEOSTOMY; INTESTINE GRAFT; INTESTINE PSEUDOOBSTRUCTION; INTESTINE RESECTION; LEAD POISONING; LUNG SMALL CELL CANCER; MANOMETRY; MEDLINE; MYASTHENIA GRAVIS; NERVE STIMULATION; NEUROGENIC BOWEL; NEUROMUSCULAR DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL STATUS; PARANEOPLASTIC NEUROPATHY; PARANEOPLASTIC SYNDROME; PARENTERAL NUTRITION; POLYOMA VIRUS; PORPHYRIA; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; PRIORITY JOURNAL; PSYCHOSOCIAL DISORDER; RADIOGRAPHY; REVIEW; SCINTIGRAPHY; SCLERODERMA; SJOEGREN SYNDROME; THYMOMA; THYROID DISEASE;

ADULT; AGED; ALGORITHMS; ANIMALS; BIOPSY; CHRONIC DISEASE; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; HUMANS; PARENTERAL NUTRITION, HOME; PATIENT CARE TEAM; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84885957457     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12496     Document Type: Review

References (243)

1. Atkins D, Best D, Briss PA, et al,. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.
2. Portincasa P, Moschetta A, Baldassarre G, et al,. Pan-enteric dysmotility, impaired quality of life and alexithymia in a large group of patients meeting ROME II criteria for irritable bowel syndrome. World J Gastroenterol 2003; 9: 2293-9.
3. Lindberg G, Tornblom H, Iwarzon M, et al,. Full-thickness biopsy findings in chronic intestinal pseudo-obstruction and enteric dysmotility. Gut 2009; 58: 1084-90.
4. Camilleri M,. Intestinal dysmotility: does the X-ray resolve the real dilemma? J Pediatr Gastroenterol Nutr 1997; 24: 100-1.
5. Knowles CH, De Giorgio R, Kapur RP, et al,. Gastrointestinal neuromuscular pathology: guidelines for histological techniques and reporting on behalf of the Gastro 2009 International Working Group. Acta Neuropathol 2009; 118: 271-301.
6. Tornblom H, Lindberg G,. A 21st century look at the spectrum of gastrointestinal motility disorders. What is dysmotility; what is functional? Gastroenterol Clin North Am 2011; 40: 715-23.
7. Camilleri M,. Diagnosis and treatment of enteric neuromuscular diseases. Clin Auton Res 2003; 13: 10-5.
8. Camilleri M, Hasler WL, Parkman HP, et al,. Measurement of gastrointestinal motility in the GI laboratory. Gastroenterology 1998; 115: 747-62.
9. Cogliandro RF, Antonucci A, De Giorgio R, et al,. Patient-reported outcomes and gut dysmotility in functional gastrointestinal disorders. Neurogastroenterol Motil 2011; 23: 1084-91.
10. Camilleri M, Parkman HP, Shafi MA, et al,. Clinical guideline: management of gastroparesis. Am J Gastroenterol 2013; 108: 18-37.
11. Jain A, Vargas HD,. Advances and challenges in the management of acute colonic pseudo-obstruction (ogilvie syndrome). Clin Colon Rectal Surg 2012; 25: 37-45.
12. Rohof WO, Boeckxstaens GE,. Treatment of the patient with achalasia. Curr Opin Gastroenterol 2012; 28: 389-94.
13. Kenny SE, Tam PK, Garcia-Barcelo M,. Hirschsprung's disease. Semin Pediatr Surg 2010; 19: 194-200.
14. Rosa ESL, Gerson L, Davila M, et al,. Clinical, radiologic, and manometric characteristics of chronic intestinal dysmotility: the Stanford experience. Clin Gastroenterol Hepatol 2006; 4: 866-73.
15. Scott SM, Picon L, Knowles CH, et al,. Automated quantitative analysis of nocturnal jejunal motor activity identifies abnormalities in individuals and subgroups of patients with slow transit constipation. Am J Gastroenterol 2003; 98: 1123-34.
16. Glia A, Lindberg G,. Antroduodenal manometry findings in patients with slow-transit constipation. Scand J Gastroenterol 1998; 33: 55-62.
17. Gunay A, Gurbuz AK, Narin Y, et al,. Gallbladder and gastric motility in patients with idiopathic slow-transit constipation. South Med J 2004; 97: 124-8.
18. Penning C, Gielkens HA, Delemarre JB, et al,. Gall bladder emptying in severe idiopathic constipation. Gut 1999; 45: 264-8.
19. Seidl H, Gundling F, Pehl C, et al,. Small bowel motility in functional chronic constipation. Neurogastroenterol Motil 2009; 21: 1278-e122.
20. Penning C, Vu MK, Delemarre JB, et al,. Proximal gastric motor and sensory function in slow transit constipation. Scand J Gastroenterol 2001; 36: 1267-73.
21. Spiller RC,. Upper gut dysmotility in slow-transit constipation: is it evidence for a pan-enteric neurological deficit in severe slow transit constipation? Eur J Gastroenterol Hepatol 1999; 11: 693-6.
22. Fruhwald S, Holzer P, Metzler H,. Gastrointestinal motility in acute illness. Wien Klin Wochenschr 2008; 120: 6-17.
23. Stanghellini V, Cogliandro RF, De Giorgio R, et al,. Natural history of chronic idiopathic intestinal pseudo-obstruction in adults: a single center study. Clin Gastroenterol Hepatol 2005; 3: 449-58.
24. Amiot A, Joly F, Alves A, et al,. Long-term outcome of chronic intestinal pseudo-obstruction adult patients requiring home parenteral nutrition. Am J Gastroenterol 2009; 104: 1262-70.
25. Jebbink HJ, vanBerge-Henegouwen GP, Akkermans LM, et al,. Small intestinal motor abnormalities in patients with functional dyspepsia demonstrated by ambulatory manometry. Gut 1996; 38: 694-700.
26. Quigley EM,. Gastrointestinal motility testing-a personal perspective. Ir Med J 1995; 88: 210-2.
27. Husebye E,. The patterns of small bowel motility: physiology and implications in organic disease and functional disorders. Neurogastroenterol Motil 1999; 11: 141-61.
28. Verhagen MA, Samsom M, Jebbink RJ, et al,. Clinical relevance of antroduodenal manometry. Eur J Gastroenterol Hepatol 1999; 11: 523-8.
29. Lindberg G, Iwarzon M, Tornblom H,. Clinical features and long-term survival in chronic intestinal pseudo-obstruction and enteric dysmotility. Scand J Gastroenterol 2009; 44: 692-9.
30. Knowles CH, de Giorgio R, Kapur RP, et al,. The London Classification of gastrointestinal neuromuscular pathology: report on behalf of the Gastro 2009 International Working Group. Gut 2010; 59: 882-7.
31. Tornblom H, Lang B, Clover L, et al,. Autoantibodies in patients with gut motility disorders and enteric neuropathy. Scand J Gastroenterol 2007; 42: 1289-93.
32. Knowles CH, Veress B, Tornblom H, et al,. Safety and diagnostic yield of laparoscopically assisted full-thickness bowel biopsy. Neurogastroenterol Motil 2008; 20: 774-9.
33. Streutker CJ, Huizinga JD, Campbell F, et al,. Loss of CD117 (c-kit)- and CD34-positive ICC and associated CD34-positive fibroblasts defines a subpopulation of chronic intestinal pseudo-obstruction. Am J Surg Pathol 2003; 27: 228-35.
34. Kellow JE,. Myenteric plexitis in enteric dysmotility: what are the implications for clinical practice? Gut 2009; 58: 1042-3.
35. De Giorgio R, Camilleri M,. Human enteric neuropathies: morphology and molecular pathology. Neurogastroenterol Motil 2004; 16: 515-31.
36. Low PA,. Autonomic neuropathies. Curr Opin Neurol 1998; 11: 531-7.
37. Vernino S, Sandroni P, Singer W, et al,. Invited article: autonomic ganglia: target and novel therapeutic tool. Neurology 2008; 70: 1926-32.
38. Camilleri M, Balm RK, Low PA,. Autonomic dysfunction in patients with chronic intestinal pseudo-obstruction. Clin Auton Res 1993; 3: 95-100.
39. Yamanaka Y, Sakakibara R, Asahina M, et al,. Chronic intestinal pseudo-obstruction as the initial feature of pure autonomic failure. J Neurol Neurosurg Psychiatry 2006; 77: 800.
40. Khurana RK, Schuster MM,. Autonomic dysfunction in chronic intestinal pseudo-obstruction. Clin Auton Res 1998; 8: 335-40.
41. Suarez GA, Opfer-Gehrking TL, Offord KP, et al,. The autonomic symptom profile: a new instrument to assess autonomic symptoms. Neurology 1999; 52: 523-8.
42. Bharucha AE, Camilleri M, Low PA, et al,. Autonomic dysfunction in gastrointestinal motility disorders. Gut 1993; 34: 397-401.
43. Abid S, Lindberg G,. Electrogastrography: poor correlation with antro-duodenal manometry and doubtful clinical usefulness in adults. World J Gastroenterol 2007; 13: 5101-7.
44. Lane SW, Pender MP,. Intestinal pseudo-obstruction complicating multiple sclerosis. Intern Med J 2005; 35: 191-2.
45. Chaudhry V, Umapathi T, Ravich WJ,. Neuromuscular diseases and disorders of the alimentary system. Muscle Nerve 2002; 25: 768-84.
46. Vernino S, Cheshire WP, Lennon VA,. Myasthenia gravis with autoimmune autonomic neuropathy. Auton Neurosci 2001; 88: 187-92.
47. Bellini M, Biagi S, Stasi C, et al,. Gastrointestinal manifestations in myotonic muscular dystrophy. World J Gastroenterol 2006; 12: 1821-8.
48. Lacy BE, Zayat E, Crowell MD,. Generalized intestinal dysmotility in a patient with syringomyelia. Am J Gastroenterol 2001; 96: 1282-5.
49. Parry-Jones A, Paine P, Ramdass R, et al,. Unexplained gastrointestinal dysmotility: the clue may lie in the brain. Gut 2011; 60: 758.
50. Simon LT, Horoupian DS, Dorfman LJ, et al,. Polyneuropathy, ophthalmoplegia, leukoencephalopathy, and intestinal pseudo-obstruction: POLIP syndrome. Ann Neurol 1990; 28: 349-60.
51. Gillis LA, Sokol RJ,. Gastrointestinal manifestations of mitochondrial disease. Gastroenterol Clin North Am 2003; 32: 789-817, v.
52. Carroll MB,. MELAS masquerading as a systemic vasculitis. J Clin Rheumatol 2007; 13: 334-7.
53. Kintarak J, Liewluck T, Sangruchi T, et al,. A novel ECGF1 mutation in a Thai patient with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). Clin Neurol Neurosurg 2007; 109: 613-6.
54. Hom XB, Lavine JE,. Gastrointestinal complications of mitochondrial disease. Mitochondrion 2004; 4: 601-7.
55. Amiot A, Tchikviladze M, Joly F, et al,. Frequency of mitochondrial defects in patients with chronic intestinal pseudo-obstruction. Gastroenterology 2009; 137: 101-9.
56. Gilbert J, Ibdah JA,. Intestinal pseudo-obstruction as a manifestation of impaired mitochondrial fatty acid oxidation. Med Hypotheses 2005; 64: 586-9.
57. Giordano C, Sebastiani M, Plazzi G, et al,. Mitochondrial neurogastrointestinal encephalomyopathy: evidence of mitochondrial DNA depletion in the small intestine. Gastroenterology 2006; 130: 893-901.
58. Giordano C, Sebastiani M, De Giorgio R, et al,. Gastrointestinal dysmotility in mitochondrial neurogastrointestinal encephalomyopathy is caused by mitochondrial DNA depletion. Am J Pathol 2008; 173: 1120-8.
59. Holmes GM,. Upper gastrointestinal dysmotility after spinal cord injury: is diminished vagal sensory processing one culprit? Front Physiol 2012; 3: 277.
60. Lorusso L, Hart IK, Ferrari D, et al,. Autonomic paraneoplastic neurological syndromes. Autoimmun Rev 2007; 6: 162-8.
61. DiBaise JK,. Paraneoplastic gastrointestinal dysmotility: when to consider and how to diagnose. Gastroenterol Clin North Am 2011; 40: 777-86.
62. Block MS, Vassallo R,. Lack of FDG uptake in small cell carcinoma associated with ANNA-1 positive paraneoplastic autonomic neuropathy. J Thorac Oncol 2008; 3: 542-4.
63. Lee HR, Lennon VA, Camilleri M, et al,. Paraneoplastic gastrointestinal motor dysfunction: clinical and laboratory characteristics. Am J Gastroenterol 2001; 96: 373-9.
64. Vernino S,. Antibody testing as a diagnostic tool in autonomic disorders. Clin Auton Res 2009; 19: 13-9.
65. Pardi DS, Miller SM, Miller DL, et al,. Paraneoplastic dysmotility: loss of interstitial cells of Cajal. Am J Gastroenterol 2002; 97: 1828-33.
66. Sandroni P, Low PA,. Other autonomic neuropathies associated with ganglionic antibody. Auton Neurosci 2009; 146: 13-7.
67. Klein CM, Vernino S, Lennon VA, et al,. The spectrum of autoimmune autonomic neuropathies. Ann Neurol 2003; 53: 752-8.
68. Hubball A, Martin JE, Lang B, et al,. The role of humoral autoimmunity in gastrointestinal neuromuscular diseases. Prog Neurobiol 2009; 87: 10-20.
69. Hubball AW, Lang B, Souza MA, et al,. Voltage-gated potassium channel (K(v) 1) autoantibodies in patients with chagasic gut dysmotility and distribution of K(v) 1 channels in human enteric neuromusculature (autoantibodies in GI dysmotility). Neurogastroenterol Motil 2012; 24: 719-28, e344.
70. Chamberlain JL, Pittock SJ, Oprescu AM, et al,. Peripherin-IgG association with neurologic and endocrine autoimmunity. J Autoimmun 2010; 34: 469-77.
71. Pande R, Leis AA,. Myasthenia gravis, thymoma, intestinal pseudo-obstruction, and neuronal nicotinic acetylcholine receptor antibody. Muscle Nerve 1999; 22: 1600-2.
72. Musthafa CP, Moosa A, Chandrashekharan PA, et al,. Intestinal pseudo-obstruction as initial presentation of thymoma. Indian J Gastroenterol 2006; 25: 264-5.
73. Viallard JF, Vincent A, Moreau JF, et al,. Thymoma-associated neuromyotonia with antibodies against voltage-gated potassium channels presenting as chronic intestinal pseudo-obstruction. Eur Neurol 2005; 53: 60-3.
74. Simonelli M, Banna GL, Santoro A,. Thymoma associated with myasthenia and autonomic anti-Hu paraneoplastic neuropathy. Tumori 2009; 95: 243-7.
75. Hammar O, Ohlsson B, Veress B, et al,. Depletion of enteric gonadotropin-releasing hormone is found in a few patients suffering from severe gastrointestinal dysmotility. Scand J Gastroenterol 2012; 47: 1165-73.
76. Petre S, Shah IA, Gilani N,. Review article: gastrointestinal amyloidosis-clinical features, diagnosis and therapy. Aliment Pharmacol Ther 2008; 27: 1006-16.
77. Ebert EC, Nagar M,. Gastrointestinal manifestations of amyloidosis. Am J Gastroenterol 2008; 103: 776-87.
78. Wang AK, Fealey RD, Gehrking TL, et al,. Patterns of neuropathy and autonomic failure in patients with amyloidosis. Mayo Clin Proc 2008; 83: 1226-30.
79. Hurlstone DP,. Iron-deficiency anemia complicating AL amyloidosis with recurrent small bowel pseudo-obstruction and hindgut sparing. J Gastroenterol Hepatol 2002; 17: 623-4.
80. Koppelman RN, Stollman NH, Baigorri F, et al,. Acute small bowel pseudo-obstruction due to AL amyloidosis: a case report and literature review. Am J Gastroenterol 2000; 95: 294-6.
81. Ohlsson B, Fork FT, Veress B, et al,. Coexistent chronic idiopathic intestinal pseudo obstruction and inflammatory bowel disease. Gut 2005; 54: 729-30.
82. Losanoff JE, Kjossev KT, Katrov ET,. Eosinophilic enterocolitis and visceral neuropathy with chronic intestinal pseudo-obstruction. J Clin Gastroenterol 1999; 28: 368-71.
83. Attwood SE,. Eosinophils and gut dysmotility. Eur J Gastroenterol Hepatol 2005; 17: 891-2.
84. Ozaki H, Hori M, Kinoshita K, et al,. Intestinal dysmotility in inflammatory bowel disease: mechanisms of the reduced activity of smooth muscle contraction. Inflammopharmacology 2005; 13: 103-11.
85. Ohama T, Hori M, Ozaki H,. Mechanism of abnormal intestinal motility in inflammatory bowel disease: how smooth muscle contraction is reduced? J Smooth Muscle Res 2007; 43: 43-54.
86. Murch S,. Allergy and intestinal dysmotility-causal or coincidental links? J Pediatr Gastroenterol Nutr 2005; 41 (Suppl. 1): S14-6.
87. Murch S,. Allergy and intestinal dysmotility-evidence of genuine causal linkage? Curr Opin Gastroenterol 2006; 22: 664-8.
88. Marie I, Herve F, Dode C, et al,. Intestinal pseudo-obstruction as a manifestation of tumor necrosis factor receptor-associated periodic syndrome. Dig Dis Sci 2006; 51: 1061-2.
89. DiBaise JK, Quigley EM,. Tumor-related dysmotility: gastrointestinal dysmotility syndromes associated with tumors. Dig Dis Sci 1998; 43: 1369-401.
90. Selgrad M, De Giorgio R, Fini L, et al,. JC virus infects the enteric glia of patients with chronic idiopathic intestinal pseudo-obstruction. Gut 2009; 58: 25-32.
91. De Giorgio R, Ricciardiello L, Naponelli V, et al,. Chronic intestinal pseudo-obstruction related to viral infections. Transplant Proc 2010; 42: 9-14.
92. Debinski HS, Kamm MA, Talbot IC, et al,. DNA viruses in the pathogenesis of sporadic chronic idiopathic intestinal pseudo-obstruction. Gut 1997; 41: 100-6.
93. Lindberg G,. Chronic intestinal pseudo-obstruction: how important is JC virus infection? Gut 2009; 58: 2-3.
94. Vassallo M, Camilleri M, Caron BL, et al,. Gastrointestinal motor dysfunction in acquired selective cholinergic dysautonomia associated with infectious mononucleosis. Gastroenterology 1991; 100: 252-8.
95. Chatila R, Kapadia CR,. Intestinal pseudoobstruction in acute Lyme disease: a case report. Am J Gastroenterol 1998; 93: 1179-80.
96. Tursi A,. Gastrointestinal motility disturbances in celiac disease. J Clin Gastroenterol 2004; 38: 642-5.
97. Sadik R, Abrahamsson H, Kilander A, et al,. Gut transit in celiac disease: delay of small bowel transit and acceleration after dietary treatment. Am J Gastroenterol 2004; 99: 2429-36.
98. Shakil A, Church RJ, Rao SS,. Gastrointestinal complications of diabetes. Am Fam Physician 2008; 77: 1697-702.
99. Phillips LK, Rayner CK, Jones KL, et al,. An update on autonomic neuropathy affecting the gastrointestinal tract. Curr Diab Rep 2006; 6: 417-23.
100. Resmini E, Parodi A, Savarino V, et al,. Evidence of prolonged orocecal transit time and small intestinal bacterial overgrowth in acromegalic patients. J Clin Endocrinol Metab 2007; 92: 2119-24.
101. Ebert EC,. The thyroid and the gut. J Clin Gastroenterol 2010; 44: 402-6.
102. Abboud B, Sayegh R, Medlej R, et al,. A rare manifestation of hypothyroidism: intestinal obstruction. Report of 2 cases and review of the literature. J Med Liban 1999; 47: 364-6.
103. Murakami S, Okushiba S, Ohno K, et al,. Malignant pheochromocytoma associated with pseudo-obstruction of the colon. J Gastroenterol 2003; 38: 175-80.
104. Vezzadini C, Toni R, Vezzadini P,. Pancreatic somatostatinoma presenting with chronic intestinal pseudo-obstruction syndrome. Minerva Gastroenterol Dietol 1996; 42: 227-31.
105. Sallam H, McNearney TA, Chen JD,. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther 2006; 23: 691-712.
106. Greydanus MP, Camilleri M,. Abnormal postcibal antral and small bowel motility due to neuropathy or myopathy in systemic sclerosis. Gastroenterology 1989; 96: 110-5.
107. Sjolund K, Bartosik I, Lindberg G, et al,. Small intestinal manometry in patients with systemic sclerosis. Eur J Gastroenterol Hepatol 2005; 17: 1205-12.
108. Singh J, Cohen S, Mehendiratta V, et al,. Effects of scleroderma antibodies and pooled human immunoglobulin on anal sphincter and colonic smooth muscle function. Gastroenterology 2012; 143: 1308-18.
109. Kawaguchi Y, Nakamura Y, Matsumoto I, et al,. Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility. Ann Rheum Dis 2009; 68: 710-4.
110. Domsic R, Fasanella K, Bielefeldt K,. Gastrointestinal manifestations of systemic sclerosis. Dig Dis Sci 2008; 53: 1163-74.
111. Di Ciaula A, Covelli M, Berardino M, et al,. Gastrointestinal symptoms and motility disorders in patients with systemic scleroderma. BMC Gastroenterol 2008; 8: 7.
112. Krishnamurthy S, Kelly MM, Rohrmann CA, et al,. Jejunal diverticulosis. A heterogenous disorder caused by a variety of abnormalities of smooth muscle or myenteric plexus. Gastroenterology 1983; 85: 538-47.
113. Kongara KR, Soffer EE,. Intestinal motility in small bowel diverticulosis: a case report and review of the literature. J Clin Gastroenterol 2000; 30: 84-6.
114. Ceccato F, Salas A, Gongora V, et al,. Chronic intestinal pseudo-obstruction in patients with systemic lupus erythematosus: report of four cases. Clin Rheumatol 2008; 27: 399-402.
115. Perlemuter G, Chaussade S, Wechsler B, et al,. Chronic intestinal pseudo-obstruction in systemic lupus erythematosus. Gut 1998; 43: 117-22.
116. Miyata M, Watanabe K, Suzuki T, et al,. Chronic intestinal pseudoobstruction ileus in a patient with rheumatoid arthritis: outcome of a stoma construction and its histopathological features. J Gastroenterol 2002; 37: 653-7.
117. Ljubich P, Parkman HP, Fisher RS, et al,. Diffuse gastrointestinal dysmotility in a patient with rheumatoid arthritis. Am J Gastroenterol 1993; 88: 1443-5.
118. Shinohara T, Hidaka T, Matsuki Y, et al,. Calcinosis cutis and intestinal pseudoobstruction in a patient with adult onset Still's disease associated with recurrent relapses of disordered coagulopathy. Intern Med 1999; 38: 516-20.
119. Zarate N, Farmer AD, Grahame R, et al,. Unexplained gastrointestinal symptoms and joint hypermobility: is connective tissue the missing link? Neurogastroenterol Motil 2010; 22: 252-e78.
120. Holzer P,. Opioid receptors in the gastrointestinal tract. Regul Pept 2009; 155: 11-7.
121. Holzer P,. Treatment of opioid-induced gut dysfunction. Expert Opin Investig Drugs 2007; 16: 181-94.
122. Rogers M, Cerda JJ,. The narcotic bowel syndrome. J Clin Gastroenterol 1989; 11: 132-5.
123. Grunkemeier DM, Cassara JE, Dalton CB, et al,. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol 2007; 5: 1126-39.
124. Richards DM, Scott NA, Shaffer JL, et al,. Opiate and sedative dependence predicts a poor outcome for patients receiving home parenteral nutrition. JPEN J Parenter Enteral Nutr 1997; 21: 336-8.
125. Palmer SE, McLean RM, Ellis PM, et al,. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry 2008; 69: 759-68.
126. Rondla S, Crane S,. A case of clozapine-induced paralytic ileus. Emerg Med J 2007; 24: e12.
127. Schutter N, Verhaar HJ, Ottervanger JP,. Intestinal pseudo-obstruction during use of baclofen. Ned Tijdschr Geneeskd 1995; 139: 1891-3.
128. Ohlsson B, Veress B, Janciauskiene S, et al,. Chronic intestinal pseudo-obstruction due to buserelin-induced formation of anti-GnRH antibodies. Gastroenterology 2007; 132: 45-51.
129. Bauer GE, Hellestrand KJ,. Letter: pseudo-obstruction due to clonidine. Br Med J 1976; 1: 769.
130. Campbell S, Thomas R, Parker A, et al,. Fludarabine induced intestinal pseudo-obstruction: case report and literature review. Eur J Gastroenterol Hepatol 2000; 12: 711-3.
131. Chiyonobu T, Noda R, Yoshida M, et al,. Intestinal pseudo-obstruction in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) associated with phenytoin therapy. Brain Dev 2008; 30: 430-3.
132. Schultz HS, Vernon B,. Intestinal pseudo-obstruction related to using verapamil. West J Med 1989; 151: 556-8.
133. Madan K, Sharma PK, Makharia G, et al,. Autonomic dysfunction due to lead poisoning. Auton Neurosci 2007; 132: 103-6.
134. Vidal A, de la Cuerda C, Luis Escat J, et al,. Chronic radiation enteritis after ovarian cancer: from home parenteral nutrition to oral diet. Clin Nutr 2006; 25: 701-4.
135. Rao SS, Camilleri M, Hasler WL, et al,. Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. Neurogastroenterol Motil 2011; 23: 8-23.
136. Saad RJ, Rao SS, Koch KL, et al,. Do stool form and frequency correlate with whole-gut and colonic transit? Results from a multicenter study in constipated individuals and healthy controls. Am J Gastroenterol 2010; 105: 403-11.
137. Soffer EE,. Small bowel motility: ready for prime time? Curr Gastroenterol Rep 2000; 2: 364-9.
138. Iwarzon M, Gardulf A, Lindberg G,. Health care use in patients with chronic intestinal dysmotility before and after introducing a specialized day-care unit. Clin Gastroenterol Hepatol 2008; 6: 893-8.
139. Bourke J, Soldan J, Silk DB, et al,. 'Idiopathic' intestinal failure-the importance of identifying and treating primary psychopathology. Neurogastroenterol Motil 2012; 24: 242-51.
140. Merlin A, Soyer P, Boudiaf M, et al,. Chronic intestinal pseudo-obstruction in adult patients: multidetector row helical CT features. Eur Radiol 2008; 18: 1587-95.
141. Hokama A, Ihama Y, Kishimoto K, et al,. Clinical Images: chronic intestinal pseudoobstruction and the "hide-bound" bowel sign. Arthritis Rheum 2007; 56: 1724.
142. Accarino A, Perez F, Azpiroz F, et al,. Abdominal distention results from caudo-ventral redistribution of contents. Gastroenterology 2009; 136: 1544-51.
143. Parry-Jones A, Paine P, Ramdass R, et al,. Unexplained gastrointestinal dysmotility: the clue may lie in the brain. Gut 2011; 60: 758, 805.
144. Nagashima T, Iwamoto M, Minota S,. Semiquantitative assessment of the intestinal motility in chronic intestinal pseudo-obstruction in systemic sclerosis and mixed connective tissue disease by Sitzmarks capsule. Mod Rheumatol 2006; 16: 330-1.
145. Parkman HP, Miller MA, Fisher RS,. Role of nuclear medicine in evaluating patients with suspected gastrointestinal motility disorders. Semin Nucl Med 1995; 25: 289-305.
146. Odunsi ST, Camilleri M,. Selected interventions in nuclear medicine: gastrointestinal motor functions. Semin Nucl Med 2009; 39: 186-94.
147. Balan K, Alwis L, Sonoda LI, et al,. Utility of whole gut transit scintigraphy in patients with chronic gastrointestinal symptoms. Nucl Med Commun 2010; 31: 328-33.
148. Bonapace ES, Maurer AH, Davidoff S, et al,. Whole gut transit scintigraphy in the clinical evaluation of patients with upper and lower gastrointestinal symptoms. Am J Gastroenterol 2000; 95: 2838-47.
149. Malagelada C, De Iorio F, Azpiroz F, et al,. New insight into intestinal motor function via noninvasive endoluminal image analysis. Gastroenterology 2008; 135: 1155-62.
150. de Iorio F, Malagelada C, Azpiroz F, et al,. Intestinal motor activity, endoluminal motion and transit. Neurogastroenterol Motil 2009; 21: 1264-e119.
151. Li H, Yan G,. A portable method for assessing gastrointestinal motility by simultaneously measuring transit time and contraction frequency. J Med Eng Technol 2008; 32: 448-55.
152. Tran K, Brun R, Kuo B,. Evaluation of regional and whole gut motility using the wireless motility capsule: relevance in clinical practice. Therap Adv Gastroenterol 2012; 5: 249-60.
153. Kuo B, Maneerattanaporn M, Lee AA, et al,. Generalized transit delay on wireless motility capsule testing in patients with clinical suspicion of gastroparesis, small intestinal dysmotility, or slow transit constipation. Dig Dis Sci 2011; 56: 2928-38.
154. Camilleri M, Thorne NK, Ringel Y, et al,. Wireless pH-motility capsule for colonic transit: prospective comparison with radiopaque markers in chronic constipation. Neurogastroenterol Motil 2010; 22: 874-82, e233.
155. Rao SS, Kuo B, McCallum RW, et al,. Investigation of colonic and whole gut transit with wireless motility capsule and radioopaque markers in constipation. Clin Gastroenterol Hepatol 2009; 7: 537-44.
156. Maqbool S, Parkman HP, Friedenberg FK,. Wireless capsule motility: comparison of the SmartPill GI monitoring system with scintigraphy for measuring whole gut transit. Dig Dis Sci 2009; 54: 2167-74.
157. Stanghellini V, Cogliandro R, Cogliandro L, et al,. Clinical use of manometry for the diagnosis of intestinal motor abnormalities. Dig Liver Dis 2000; 32: 532-41.
158. Smout AJ,. Manometry of the gastrointestinal tract: toy or tool? Scand J Gastroenterol Suppl 2001; 2001: 22-8.
159. Camilleri M, Bharucha AE, di Lorenzo C, et al,. American Neurogastroenterology and Motility Society consensus statement on intraluminal measurement of gastrointestinal and colonic motility in clinical practice. Neurogastroenterol Motil 2008; 20: 1269-82.
160. Malcolm A, Kellow J,. Small bowel motility. Curr Opin Gastroenterol 2002; 18: 187-91.
161. Hansen MB,. Small intestinal manometry. Physiol Res 2002; 51: 541-56.
162. Soffer EE, Thongsawat S,. Small bowel manometry: short or long recording sessions? Dig Dis Sci 1997; 42: 873-7.
163. Hernandez JC, Ratuapli SK, Burdick GE, et al,. Interrater and intrarater agreement of the chicago classification of achalasia subtypes using high-resolution esophageal manometry. Am J Gastroenterol 2012; 107: 207-14.
164. Braden B,. Methods and functions: breath tests. Best Pract Res Clin Gastroenterol 2009; 23: 337-52.
165. Saad RJ, Chey WD,. Breath tests for gastrointestinal disease: the real deal or just a lot of hot air? Gastroenterology 2007; 133: 1763-6.
166. Simren M, Stotzer PO,. Use and abuse of hydrogen breath tests. Gut 2006; 55: 297-303.
167. Yu D, Cheeseman F, Vanner S,. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut 2011; 60: 334-40.
168. Wutzke KD, Heine WE, Plath C, et al,. Evaluation of oro-coecal transit time: a comparison of the lactose-[13C, 15N]ureide 13CO2- and the lactulose H2-breath test in humans. Eur J Clin Nutr 1997; 51: 11-9.
169. Urita Y, Watanabe T, Maeda T, et al,. Breath hydrogen gas concentration linked to intestinal gas distribution and malabsorption in patients with small-bowel pseudo-obstruction. Biomark Insights 2009; 4: 9-15.
170. Kerckhoffs AP, Visser MR, Samsom M, et al,. Critical evaluation of diagnosing bacterial overgrowth in the proximal small intestine. J Clin Gastroenterol 2008; 42: 1095-102.
171. Silk DB,. Chronic idiopathic intestinal pseudo-obstruction: the need for a multidisciplinary approach to management. Proc Nutr Soc 2004; 63: 473-80.
172. Matarese LE,. Establishment of an intestinal rehabilitation program in an international tertiary care center. Nutrition 2003; 19: 70-2.
173. Coret F, Bosca I, Fratalia L, et al,. Long-lasting remission after rituximab treatment in a case of anti-Hu-associated sensory neuronopathy and gastric pseudoobstruction. J Neurooncol 2009; 93: 421-3.
174. Badari A, Farolino D, Nasser E, et al,. A novel approach to paraneoplastic intestinal pseudo-obstruction. Support Care Cancer 2012; 20: 425-8.
175. De Giorgio R, Guerrini S, Barbara G, et al,. Inflammatory neuropathies of the enteric nervous system. Gastroenterology 2004; 126: 1872-83.
176. Stanghellini V, Corinaldesi R, Ghidini C, et al,. Reversibility of gastrointestinal motor abnormalities in chronic intestinal pseudo-obstruction. Hepatogastroenterology 1992; 39: 34-8.
177. Holzer P,. Opioid antagonists for prevention and treatment of opioid-induced gastrointestinal effects. Curr Opin Anaesthesiol 2010; 23: 616-22.
178. Sandgren K, Larsson LT, Ekblad E,. Widespread changes in neurotransmitter expression and number of enteric neurons and interstitial cells of Cajal in lethal spotted mice: an explanation for persisting dysmotility after operation for Hirschsprung's disease? Dig Dis Sci 2002; 47: 1049-64.
179. Schang JC, Devroede G,. Beneficial effects of naloxone in a patient with intestinal pseudoobstruction. Am J Gastroenterol 1985; 80: 407-11.
180. Wilder-Smith CH, Bettiga A,. The analgesic tramadol has minimal effect on gastrointestinal motor function. Br J Clin Pharmacol 1997; 43: 71-5.
181. Wilder-Smith CH, Hill L, Osler W, et al,. Effect of tramadol and morphine on pain and gastrointestinal motor function in patients with chronic pancreatitis. Dig Dis Sci 1999; 44: 1107-16.
182. Maurer AH, Krevsky B, Knight LC, et al,. Opioid and opioid-like drug effects on whole-gut transit measured by scintigraphy. J Nucl Med 1996; 37: 818-22.
183. Pollock AB, Tegeler ML, Morgan V, et al,. Morphine to methadone conversion: an interpretation of published data. Am J Hosp Palliat Care 2011; 28: 135-40.
184. Olesen SS, Graversen C, Bouwense SA, et al,. Quantitative sensory testing predicts pregabalin efficacy in painful chronic pancreatitis. PLoS ONE 2013; 8: e57963.
185. Tan T, Barry P, Reken S, et al,. Pharmacological management of neuropathic pain in non-specialist settings: summary of NICE guidance. BMJ 2010; 340: c1079.
186. Celebi N, Sahin A, Canbay O, et al,. Abdominal pain related to mitochondrial neurogastrointestinal encephalomyopathy syndrome may benefit from splanchnic nerve blockade. Paediatr Anaesth 2006; 16: 1073-6.
187. Herbert MK, Holzer P,. Standardized concept for the treatment of gastrointestinal dysmotility in critically ill patients-current status and future options. Clin Nutr 2008; 27: 25-41.
188. Camilleri M, Brown ML, Malagelada JR,. Impaired transit of chyme in chronic intestinal pseudoobstruction. Correction by cisapride. Gastroenterology 1986; 91: 619-26.
189. Camilleri M, Balm RK, Zinsmeister AR,. Determinants of response to a prokinetic agent in neuropathic chronic intestinal motility disorder. Gastroenterology 1994; 106: 916-23.
190. Camilleri M, Balm RK, Zinsmeister AR,. Symptomatic improvement with one-year cisapride treatment in neuropathic chronic intestinal dysmotility. Aliment Pharmacol Ther 1996; 10: 403-9.
191. Emmanuel AV, Kamm MA, Roy AJ, et al,. Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction-a double-blind, placebo-controlled, cross-over, multiple n = 1 study. Aliment Pharmacol Ther 2012; 35: 48-55.
192. Boeckxstaens GE, Bartelsman JF, Lauwers L, et al,. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am J Gastroenterol 2002; 97: 194-7.
193. Emmanuel AV, Shand AG, Kamm MA,. Erythromycin for the treatment of chronic intestinal pseudo-obstruction: description of six cases with a positive response. Aliment Pharmacol Ther 2004; 19: 687-94.
194. Lecomte T, Cavicchi M, Delchier JC,. Small bowel pseudo-obstruction revealing an early scleroderma. Long-term efficacy of octreotide and erythromycin. Gastroenterol Clin Biol 2000; 24: 361-3.
195. Minami T, Nishibayashi H, Shinomura Y, et al,. Effects of erythromycin in chronic idiopathic intestinal pseudo-obstruction. J Gastroenterol 1996; 31: 855-9.
196. Moshiree B, McDonald R, Hou W, et al,. Comparison of the effect of azithromycin versus erythromycin on antroduodenal pressure profiles of patients with chronic functional gastrointestinal pain and gastroparesis. Dig Dis Sci 2010; 55: 675-83.
197. Chini P, Toskes PP, Waseem S, et al,. Effect of azithromycin on small bowel motility in patients with gastrointestinal dysmotility. Scand J Gastroenterol 2012; 47: 422-7.
198. Karamanolis G, Tack J,. Promotility medications-now and in the future. Dig Dis 2006; 24: 297-307.
199. Bharucha AE, Low P, Camilleri M, et al,. A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation. Gut 2013; 62: 708-15.
200. Bharucha AE, Low PA, Camilleri M, et al,. Pilot study of pyridostigmine in constipated patients with autonomic neuropathy. Clin Auton Res 2008; 18: 194-202.
201. Pasha SF, Lunsford TN, Lennon VA,. Autoimmune gastrointestinal dysmotility treated successfully with pyridostigmine. Gastroenterology 2006; 131: 1592-6.
202. Sorhaug S, Steinshamn SL, Waldum HL,. Octreotide treatment for paraneoplastic intestinal pseudo-obstruction complicating SCLC. Lung Cancer 2005; 48: 137-40.
203. Haruma K, Wiste JA, Camilleri M,. Effect of octreotide on gastrointestinal pressure profiles in health and in functional and organic gastrointestinal disorders. Gut 1994; 35: 1064-9.
204. Bassotti G, Germani U, Calcara C, et al,. Effects of octreotide on manometric variables in patients with neuropathic abnormalities of the small bowel. Dig Dis Sci 1997; 42: 1634-9.
205. Perlemuter G, Cacoub P, Chaussade S, et al,. Octreotide treatment of chronic intestinal pseudoobstruction secondary to connective tissue diseases. Arthritis Rheum 1999; 42: 1545-9.
206. Soudah HC, Hasler WL, Owyang C,. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991; 325: 1461-7.
207. Quigley EM, Quera R,. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology 2006; 130: S78-90.
208. Yokota T, Suda T, Tsukioka S, et al,. The striking effect of hyperbaric oxygenation therapy in the management of chronic idiopathic intestinal pseudo-obstruction. Am J Gastroenterol 2000; 95: 285-8.
209. Andreyev HJ, Davidson SE, Gillespie C, et al,. Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer. Gut 2012; 61: 179-92.
210. Benjamin J, Singh N, Makharia GK,. Enteral nutrition for severe malnutrition in chronic intestinal pseudo-obstruction. Nutrition 2010; 26: 502-5.
211. Scolapio JS, Ukleja A, Bouras EP, et al,. Nutritional management of chronic intestinal pseudo-obstruction. J Clin Gastroenterol 1999; 28: 306-12.
212. Kamata N, Oshitani N, Suekane T, et al,. Novel management of chronic idiopathic intestinal pseudo-obstruction. Am J Gastroenterol 2009; 104: 2360-2.
213. Mann SD, Debinski HS, Kamm MA,. Clinical characteristics of chronic idiopathic intestinal pseudo-obstruction in adults. Gut 1997; 41: 675-81.
214. Warner E, Jeejeebhoy KN,. Successful management of chronic intestinal pseudo-obstruction with home parenteral nutrition. JPEN J Parenter Enteral Nutr 1985; 9: 173-8.
215. Mullady DK, O'Keefe SJ,. Treatment of intestinal failure: home parenteral nutrition. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 492-504.
216. Lal S, Teubner A, Shaffer JL,. Review article: intestinal failure. Aliment Pharmacol Ther 2006; 24: 19-31.
217. Mughal MM, Irving MH,. Treatment of end stage chronic intestinal pseudo-obstruction by subtotal enterectomy and home parenteral nutrition. Gut 1988; 29: 1613-7.
218. Pitt HA, Mann LL, Berquist WE, et al,. Chronic intestinal pseudo-obstruction. Management with total parenteral nutrition and a venting enterostomy. Arch Surg 1985; 120: 614-8.
219. Massironi S, Ulivieri FM, Marchelli D, et al,. Reduced bone mineral density in chronic intestinal idiopathic pseudo-obstruction. Am J Gastroenterol 2008; 103: 1579-81.
220. Andersson S, Lonroth H, Simren M, et al,. Gastric electrical stimulation for intractable vomiting in patients with chronic intestinal pseudoobstruction. Neurogastroenterol Motil 2006; 18: 823-30.
221. Yin J, Chen JD,. Mechanisms and potential applications of intestinal electrical stimulation. Dig Dis Sci 2010; 55: 1208-20.
222. Schuffler MD, Deitch EA,. Chronic idiopathic intestinal pseudo-obstruction. A surgical approach. Ann Surg 1980; 192: 752-61.
223. Schuffler MD, Rohrmann CA, Chaffee RG, et al,. Chronic intestinal pseudo-obstruction. A report of 27 cases and review of the literature. Medicine (Baltimore) 1981; 60: 173-96.
224. Stanghellini V, Cogliandro RF, De Giorgio R, et al,. Natural history of intestinal failure induced by chronic idiopathic intestinal pseudo-obstruction. Transplant Proc 2010; 42: 15-8.
225. Murr MM, Sarr MG, Camilleri M,. The surgeon's role in the treatment of chronic intestinal pseudoobstruction. Am J Gastroenterol 1995; 90: 2147-51.
226. Gibbons JC, Sullivan JF,. Chronic idiopathic pseudo-obstructive bowel disease. Am J Gastroenterol 1978; 70: 306-13.
227. Chun C, Aulakh S, Komlos F, et al,. Tube to freedom: use of a venting jejunostomy in a patient with chronic intestinal pseudo-obstruction. Dig Dis Sci 2012; 57: 3076-9.
228. Thompson AR, Pearson T, Ellul J, et al,. Percutaneous endoscopic colostomy in patients with chronic intestinal pseudo-obstruction. Gastrointest Endosc 2004; 59: 113-5.
229. Glia A, Akerlund JE, Lindberg G,. Outcome of colectomy for slow-transit constipation in relation to presence of small-bowel dysmotility. Dis Colon Rectum 2004; 47: 96-102.
230. Shibata C, Naito H, Funayama Y, et al,. Surgical treatment of chronic intestinal pseudo-obstruction: report of three cases. Surg Today 2003; 33: 58-61.
231. Ghirardo S, Sauter B, Levy G, et al,. Primary intestinal autoimmune disease as a cause of chronic intestinal pseudo-obstruction. Gut 2005; 54: 1206-7.
232. Lauro A, Zanfi C, Ercolani G, et al,. Twenty-five consecutive isolated intestinal transplants in adult patients: a five-year clinical experience. Clin Transplant 2007; 21: 177-85.
233. Masetti M, Cautero N, Lauro A, et al,. Three-year experience in clinical intestinal transplantation. Transplant Proc 2004; 36: 309-11.
234. Masetti M, Di Benedetto F, Cautero N, et al,. Intestinal transplantation for chronic intestinal pseudo-obstruction in adult patients. Am J Transplant 2004; 4: 826-9.
235. Pironi L, Joly F, Forbes A, et al,. Long-term follow-up of patients on home parenteral nutrition in Europe: implications for intestinal transplantation. Gut 2011; 60: 17-25.
236. Micci MA, Pasricha PJ,. Neural stem cells for the treatment of disorders of the enteric nervous system: strategies and challenges. Dev Dyn 2007; 236: 33-43.
237. Joly F, Amiot A, Messing B,. Nutritional support in the severely compromised motility patient: when and how? Gastroenterol Clin North Am 2011; 40: 845-51.
238. Iwarzon M, Gardulf A, Lindberg G,. Functional status, health-related quality of life and symptom severity in patients with chronic intestinal pseudo-obstruction and enteric dysmotility. Scand J Gastroenterol 2009; 44: 700-7.
239. Scolapio JS, Fleming CR, Kelly DG, et al,. Survival of home parenteral nutrition-treated patients: 20 years of experience at the Mayo Clinic. Mayo Clin Proc 1999; 74: 217-22.
240. Lloyd DA, Vega R, Bassett P, et al,. Survival and dependence on home parenteral nutrition: experience over a 25-year period in a UK referral centre. Aliment Pharmacol Ther 2006; 24: 1231-40.
241. Massa R, Tessa A, Margollicci M, et al,. Late-onset MNGIE without peripheral neuropathy due to incomplete loss of thymidine phosphorylase activity. Neuromuscul Disord 2009; 19: 837-40.
242. Finsterer J,. Overview on visceral manifestations of mitochondrial disorders. Neth J Med 2006; 64: 61-71.
243. De Giorgio R, Cogliandro RF, Barbara G, et al,. Chronic intestinal pseudo-obstruction: clinical features, diagnosis, and therapy. Gastroenterol Clin North Am 2011; 40: 787-807.